The 12-month programme is designed to provide multidisciplinary training in biomedical innovation, regulatory science, commercialisation strategy and healthcare product management.

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development ...

The vaccine maker’s shots involve the successful mRNA technology used in the Covid vaccines. Health Secretary Robert F.

Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence ...

The crop protection chemical maker FMC has retained financial and legal advisers to conduct a strategic review that may lead ...

In the fourth quarter of 2025, the Harbor SMID Cap Value ETF returned 3.67% (NAV), outperforming its benchmark, the Russell ...

Following the company's October reporting of vastly disappointing third-quarter 2025 financial results, Fiserv stock plunged, ...

Chinese contract drug maker forecasts 46.3% profit rise and signals continued growth despite US political scrutiny WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.

Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed ...

Bourse within 0.4 points of all-time high; James Hardie quarterly beat; $A hits three-year high; CBA betters expectations; ...

Ethereum price remained above $2,000 as the crypto market experienced a period of consolidation. Over the past week, ETH saw ...

Women in STEM bring diverse perspectives that are especially valuable in rare disease research. These conditions are complex and require innovative thinking. Attention to detail, empathy, and ...